Cover Image
市場調查報告書

子宮癌的開發中產品分析

Uterine Cancer - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 213073
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
子宮癌的開發中產品分析 Uterine Cancer - Pipeline Review, H2 2014
出版日期: 2014年09月10日 內容資訊: 英文 66 Pages
簡介

子宮癌是女性生殖系統最為常見的一種癌症。最初是子宮內部的正常細胞轉變成腫瘤,自主且以急速之勢增殖,形成被稱為腫瘤的肉塊。主要症狀有骨痛及體重減少、下腹部(胃部下方)的膨脹及腫脹等。主要致病因素有年老及肥胖、遺傳性體質、放射線治療、性別等。主要治療法有外科手術及化療、放射線療法等。

本報告提供全球各國治療子宮癌用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

子宮癌概要

治療藥的開發

  • 子宮癌用開發中產品:概要
  • 子宮癌用開發中產品:比較分析

各企業開發中的子宮癌治療藥

大學/研究機關研究中的子宮癌治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

子宮癌治療藥:開發中的產品一覽(各企業)

子宮癌治療藥:研究中的產品一覽(大學/研究機關別)

子宮癌治療藥的開發企業

  • Azaya Therapeutics Incorporated
  • EndoCeutics, Inc.
  • Sunshine Biopharma, Inc.

子宮癌:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • acolbifene hydrochloride
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • angiotensin1-7
  • Docetaxel ·微脂體
  • Adva-27a
  • Adva-32a
  • Compound-2

子宮癌治療藥:開發中產品的最新趨勢

子宮癌治療藥:暫停開發的產品

子宮癌相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全5件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5531IDB

Summary

Global Markets Direct's, 'Uterine Cancer - Pipeline Review, H2 2014', provides an overview of the Uterine Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uterine Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uterine Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uterine Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Uterine Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uterine Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Uterine Cancer - Overview
    • Pipeline Products for Uterine Cancer - Comparative Analysis
  • Uterine Cancer - Therapeutics under Development by Companies
  • Uterine Cancer - Therapeutics under Investigation by Universities/Institutes
  • Uterine Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Uterine Cancer - Products under Development by Companies
  • Uterine Cancer - Products under Investigation by Universities/Institutes
  • Uterine Cancer - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Azaya Therapeutics Incorporated
    • EndoCeutics, Inc.
    • Karyopharm Therapeutics, Inc.
  • Uterine Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acolbifene hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel liposomal - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVX-ONCO-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Adva-27a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit GARFT for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Uterine Cancer - Recent Pipeline Updates
  • Uterine Cancer - Dormant Projects
  • Uterine Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 09, 2014: Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
      • Aug 12, 2013: Advanomics wins research grant for cancer drug candidate
      • Jun 19, 2013: Sunshine Biopharma's Anticancer Drug Candidate Adva-27a Is Unaffected By Recent Supreme Court Ruling On Patentability Of Human Genes
      • Jan 15, 2013: Advanomics Files New Patent Application For Multidrug Resistance Adva-27a Anticancer Compound
      • Dec 10, 2012: Sunshine Biopharma Completes Another IND-enabling Study Of Adva-27a
      • Jun 13, 2012: Azaya Therapeutics Reports Phase I Clinical Trial Results Of ATI-1123
      • May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Uterine Cancer, H2 2014
  • Number of Products under Development for Uterine Cancer - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Uterine Cancer - Pipeline by GlaxoSmithKline plc, H2 2014
  • Uterine Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014
  • Uterine Cancer - Pipeline by EndoCeutics, Inc., H2 2014
  • Uterine Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Uterine Cancer Therapeutics - Recent Pipeline Updates, H2 2014
  • Uterine Cancer - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Uterine Cancer, H2 2014
  • Number of Products under Development for Uterine Cancer - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top